Literature DB >> 6981695

Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin.

G Nolan, P Moivor, H Levison, P C Fleming, M Corey, R Gold.   

Abstract

The effect of prophylactic antibiotics on bacterial colonization of the respiratory tract and on general progression of cystic fibrosis was studied in a two-year prospective study of 47 mildly to moderately affected patients. One group of patients received inhaled cephaloridine and the other received no inhaled antibiotic; both groups received cloxacillin orally. Carriage of Haemophilus influenzae was greater in the group not receiving inhaled antibiotic (55% vs 20%). Rates of carriage of Staphylococcus aureus (23%). Pseudomonas aeruginosa (greater than 90%). Pseudomonas cepacia (45%), and other organisms were similar in both groups. There were no significant differences between the two groups in incidence of respiratory tract infections or hospital admissions, clinical scores, radiologic scores, or rate of change of pulmonary function. Although continuous antistaphylococcal antibiotic prophylaxis may be successful in suppressing colonization with S. aureus, it may also contribute to the high rates of carriage of Ps. aeruginosa and Ps. cepacia observed in patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981695     DOI: 10.1016/s0022-3476(82)80726-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  21 in total

Review 1.  Cystic fibrosis. Infection and immunity to Staphylococcus aureus and Haemophilus influenzae.

Authors:  D P Greenberg; H R Stutman
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

2.  Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung.

Authors:  D A Groneberg; P R Eynott; F Döring; Q Thai Dinh; T Oates; P J Barnes; K F Chung; H Daniel; A Fischer
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

3.  Pseudomonas cepacia in cystic fibrosis.

Authors:  D E Stableforth; D L Smith
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

4.  Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake.

Authors:  D A Groneberg; M Nickolaus; J Springer; F Döring; H Daniel; A Fischer
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 5.  Aerosol antibiotic treatment in cystic fibrosis.

Authors:  J M Littlewood; S W Smye; H Cunliffe
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

Review 6.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 7.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 8.  The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis.

Authors:  O C Tablan; W J Martone; W R Jarvis
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

9.  Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis.

Authors:  D J Touw; F A Jacobs; R W Brimicombe; H G Heijerman; W Bakker; D D Briemer
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

10.  Characterization of Pseudomonas cepacia isolates from patients with cystic fibrosis.

Authors:  A I McKevitt; D E Woods
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.